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Cisplatin-induced posterior reversible
encephalopathy syndrome and successful
re-treatment in a patient with non-seminomatous
germ cell tumor: a case report
Muhammad Nauman Zahir*, Nehal Masood and Munira Shabbir-Moosajee
Abstract
Introduction: Cisplatin is a platinum compound that has revolutionized the treatment of various solid organ
tumors. Cisplatin is associated with a variety of side effects and has recently been indicted in the development of
posterior reversible encephalopathy syndrome. Posterior reversible encephalopathy syndrome is a potentially
reversible condition, with the mainstay of therapy being correction of the underlying cause and withdrawal of the
offending drug. However, there are no clear guidelines regarding the possibility of subsequent re-treatment with
the causative agent.
Case presentation: A 23-year-old Asian man presented to our Emergency Department with a four-month history
of concomitant abdominal pain and backache and a two-week history of left-sided leg swelling. Diagnostic
investigations revealed bilateral pulmonary embolism, extensive deep venous thrombosis and widespread lung and
liver metastatic deposits with abdomino-pelvic lymphadenopathy. His biopsy and tumor markers were consistent
with non-seminomatous germ cell tumor and he was subsequently started on an initial cycle of cisplatin and
etoposide chemotherapy. On the second day of treatment he developed posterior reversible encephalopathy
syndrome clinically and radiologically. Cisplatin was stopped for the next two days while etoposide was continued,
resulting in complete resolution of his symptoms. He was re-challenged with cisplatin on day five of chemotherapy
because a platin-based chemotherapy regimen was his only hope of potential cure. He tolerated it well, with no
recurrence of his neurological symptoms and the remainder of his in-patient stay remained uneventful. He was
discharged on day eight. He has since then completed treatment and is currently in remission.
Conclusions: The occurrence of posterior reversible encephalopathy syndrome after cisplatin use has been well
reported in the literature. We strongly believe that our patient also developed posterior reversible encephalopathy
syndrome secondary to cisplatin. The uniqueness of our patient’s case lies in the successful re-treatment of our
patient with the offending drug. To the best of our knowledge, this is the first instance where a patient was
successfully re-treated with cisplatin after having developed posterior reversible encephalopathy syndrome as a
result of cisplatin use. The excellent response to re-treatment without recurrence of neurological symptoms in our
patient’s case provides insight into re-treatment as an option in scenarios where treatment options are limited.
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Introduction
Cisplatin is a platinum compound which has revolutio-
nized the treatment of various solid organ tumors and
since its introduction in the 1970s has become the back-
bone of many chemotherapeutic regimens. Cisplatin is
associated with a variety of side effects, the most common
being nausea, vomiting, nephrotoxicity, ototoxicity and
neurotoxicity [1]. The neurotoxicity usually manifests in
the form of an axonal sensory neuropathy as peripheral
nerves are exposed to the highest levels of cisplatin with re-
sultant deposition of metal metabolites in these nerves [2].
Central nervous system (CNS) neurotoxicity of cisplatin is
rare, but has been well documented in the medical litera-
ture. An array of CNS disorders including seizures, hemi-
paresis, cortical blindness, aphasia and coma have been
attributed to cisplatin therapy [3]. Recently, cisplatin has
been reported to cause posterior reversible encephalopathy
syndrome (PRES).
PRES is a clinico-radiological entity characterized by the
onset of a variety of neurological manifestations associated
with transient changes typically in the posterior circula-
tion of the brain [2]. The commonly associated neuro-
logical symptoms include headache, seizures, confusion
and visual disturbances. The exact pathogenesis of PRES
remains unclear; however, two factors are known to pre-
dispose patients to the development of PRES: disordered
cerebral autoregulation and endothelial damage. PRES
secondary to cytotoxic chemotherapy is thought to be pre-
cipitated by the direct toxic effect of the drug on the cere-
bral vascular endothelium. Endothelial damage results in
capillary leakage, disruption of the blood brain barrier,
axonal swelling and development of vasogenic edema,
which is a hallmark feature of PRES. Vasogenic edema
and autoregulatory failure of the cerebral circulation
in turn can lead to a decrease in cerebral perfusion
which results in the clinical manifestations of PRES [4,5].
Clinically, it is characterized by subacute development of
headache, seizures, confusion and visual disturbance and
occasionally hypertensive crisis [2]. These symptoms occur
as a result of vasogenic edema in the parietal and occipital
lobes, which are preferentially involved [4].
Radiographically, PRES presents on magnetic resonance
imaging (MRI) scans as edema symmetrically affecting the
subcortical white matter most commonly in the posterior
cerebral hemispheres. It is important to note, however, that
any region of the CNS can be affected [5,6]. The most
common MRI abnormality is punctate or confluent areas
of increased signal on proton density and T2-weighted and
fluid attenuated inversion recovery (FLAIR) images. Add-
itional MRI features can include gyriform signal enhance-
ment following the administration of gadolinium, petechial
and large parenchymal hemorrhages, hypo or iso-intense
signal on diffusion weighted imaging and increased signal
on apparent diffusion coefficient (ADC) maps [7].
A wide variety of medical conditions have been impli-
cated with PRES. The more frequently reported associ-
ation is with hypertensive encephalopathy, eclampsia and
use of immunosuppressive drugs [5]. Various cytotoxic,
immunosuppressive and biological agents including cis-
platin have been indicted in the development of PRES [8].
PRES, as the name suggests, is a potentially reversible
condition, with the fundamental step in treatment being
correction of the underlying cause and withdrawal of the
offending drug. However, there are no clear guidelines on
the possibility of re-treatment with the causative agent.
Case presentation
We report the case of a 23-year-old Asian man who
presented to our Emergency Department (ED) with a
four-month history of concomitant abdominal pain and
backache and a two-week history of left-sided leg swelling.
An abdominal ultrasonogram performed for his com-
plaints revealed a soft tissue mass involving the prostate,
abutting the anterior rectal wall and the urinary bladder
along with significant para-aortic lymphadenopathy.
He was in respiratory distress on presentation to the
ED. Further investigation showed bilateral pulmonary
embolism due to extensive deep venous thrombosis
(DVT) involving both lower limbs and extending up to the
inferior vena cava (IVC) for which low-molecular-weight
heparin (LMWH) was initiated. Computed tomography
(CT) scans additionally revealed extensive lung and liver
metastatic deposits along with conglomerate abdomino-
pelvic lymphadenopathy. An ultrasonogram of the testes
was negative for any intra-testicular or extra-testicular
mass lesion. Given his relatively young age at presentation,
a retro-peritoneal germ cell tumor was suspected.
The serum lactate dehydrogenase (LDH), α-fetoprotein
(AFP) and β-human chorionic gonadotropin (β-HCG)
levels were 7596IU/L, 88.5IU/mL and 21,753mIU/mL,
respectively. Biopsy of the abdominal adenopathy was
consistent with a non-seminomatous germ cell tumor
with a prominent yolk sac tumor component. Pulmonary
function tests with diffusing capacity of the lung for car-
bon monoxide (DLCO) were performed, which revealed
the DLCO to be only 46 percent of the predicted value.
Our patient was established as having a stage IIIC (poor
risk) non-seminomatous germ cell tumor and was subse-
quently started on cisplatin (20mg/m2 on days one to five)
and etoposide (100mg/m2 on days one to five). Bleomycin
was omitted from the regimen due to the poor DLCO. On
the evening of day two of chemotherapy, he started having
hypertensive episodes with systolic blood pressures ranging
from 150 to 170mmHg and diastolic pressures in the range
of 100 to 110mmHg. Within a few hours, he developed a
tonic clonic seizure that was aborted by intravenous diaze-
pam. He was also started on calcium channel blockers for
management of hypertension. He then started to complain
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of persistent blurring of vision once fully conscious from
the post-ictal phase. His pupillary reflexes and fundoscopy
were normal. A neurological examination revealed hyper-
reflexia of the lower limbs. Investigations excluded a meta-
bolic abnormality as the cause of seizure. An MRI scan of
the brain showed multiple abnormal signal intensity areas
involving the peri-ventricular, posterior parietal and oc-
cipital regions bilaterally which were hyperintense on T2-
weighted images, hypointense on T1-weighted images and
showed patchy post-contrast enhancement with no diffu-
sion restriction (Figure 1). The findings were reported to
be consistent with PRES. Cisplatin was withheld for the
next two days as it was thought to be the most probable
cause of PRES, and chemotherapy with single agent etopo-
side was continued. At 48 hours after the seizure and the
withdrawal of cisplatin, our patient was significantly better
with no further seizure episodes and almost complete
resolution of his visual symptoms. His blood pressure had
also been controlled with anti-hypertensive medications.
At this point we decided to resume cisplatin, because a
platinum-based regimen was his only hope of potential cure.
Under close surveillance, our patient was re-challenged with
cisplatin at 20mg/m2 on day five of chemotherapy. He tole-
rated it well with no recurrence of neurological symptoms,
and the remainder of his in-patient stay remained unevent-
ful. He was discharged on day eight of chemotherapy with
complete resolution of symptoms.
He then went on to complete three additional cycles
of cisplatin and etoposide with no dose reductions, with
no further neurological complications. An interim ana-
lysis of disease response after two cycles was significant
for normalization of LDH and β-HCG levels and a greater
than 95 percent decline in AFP. CT scans showed signifi-
cant improvement in disease process. Results of a brain
MRI scan performed at the same time as this follow up
were normal (Figure 2).
Post-treatment CT scans showed complete resolution of
his liver and lung lesions but a residual retro-peritoneal
nodal mass. Tumor markers (LDH, AFP and β-HCG) had
all returned to within normal limits. As per international
guidelines, he subsequently underwent resection of the
residual nodal mass. Pathology was consistent with
Figure 1 Posterior reversible encephalopathy syndrome after cisplatin treatment. Bilateral and symmetrical abnormal intensity areas are
identified in the occipital lobes involving the cortical and subcortical locations. These are hypointense on T1-weighted images (A) and
hyperintense on T2-weighted images (B), showing minimal patchy post-contrast enhancement (C) with no diffusion restriction (D).
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fibrocollagenous tissue exhibiting extensive fibrosis, but
no viable tumor.
He is currently 90 days post-surgery and has recovered
well. Post-operative scans show no evidence of disease.
His tumor markers continue to remain within normal
limits.
Conclusions
In the cases of PRES due to cisplatin reported to date,
development of the syndrome led to discontinuation of
cisplatin with resultant resolution of the symptoms. We
strongly believe that our patient also developed PRES sec-
ondary to cisplatin. The fact that his symptoms resolved
completely after withdrawal of cisplatin despite continu-
ation of etoposide, which was the only other chemothera-
peutic drug in the regimen, led us to this conclusion.
The uniqueness of our case does not lie in the devel-
opment of PRES secondary to cisplatin use, but rather
in the successful re-treatment of our patient with the
offending drug once the acute symptomatology had
subsided. The decision to re-treat with cisplatin was
taken because platinum based regimens form the back-
bone of treatment of germ cell tumors. It was decided
that in our patient’s case permanent withdrawal of cis-
platin from the regimen would severely compromise
our efforts of effectively treating a potentially curable
malignancy. Carboplatin could have been used as an al-
ternative to cisplatin for further treatment, but has
been shown to be inferior in efficacy to the former [9]
and was hence not contemplated.
To the best of our knowledge, this is the first in-
stance when a patient was successfully re-treated with
cisplatin after having developed PRES. The only other
example in the literature is of re-treatment with beva-
cizumab in a patient with glioblastoma [10].
The excellent response to re-treatment without recur-
rence of neurological symptoms in our patient’s case pro-
vides insight that the possibility of re-treatment with the
offending agent may be an option in scenarios where other
interventions are limited. In the field of medical oncology
where curative therapeutic options may sometimes be very
limited, this possibility of re-treatment could be invaluable.
Figure 2 Magnetic resonance imaging scan of the brain six weeks after initial treatment with cisplatin. The changes of posterior
reversible encephalopathy syndrome have resolved in both T1-weighted and T2-weighted images (A,B). The T1 post-contrast (C) and
diffusion-weighted images (D) are also normal.
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However, the ultimate safety of this approach will require
additional evaluation.
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